Ann: Dimerix presentation at Bioshares Biotech Summit, page-22

The only useful information to come out of this presentation IMO, which everybody seems to have ignored, is the recruitment: 72% of the way towards the first target of 144, means they're only at 104. True target is 286, word on the street is FDA unlikely to accept a trial that's only 50% completed based on proteinuria.
But let's indulge the 144 target for a moment. DXB announced 72nd pt randomised last July. They've managed 32 more in the last 12 months= roughly 2.5 patients per month only. Don't need a calculator, to get the remaining 40 to hit 144 requires another 16 months at the current rate! Then add on 8 more months for the endpoint, takes this to July 2026 just for the interim.
@vintage, you still confident about your prediction you made last month that they'd have the 144 by this Oct/Nov? I thought you said there is a big expansion in trial sites. They're miles behind. How do they justify mid 2025 for the interim based on these facts? I don't think any China hospitals are even open for the trial is that right? Could that be why no China partner yet?
At the current rate, to get the remaining 182 to complete full trial is still 6 years away. Very worrying.
Can't imagine many license partners wanting to show patience and hang around while this trial meanders to the finish line unless there is a seismic improvement in recruitment performance, I'm sure they all have lot of other commercially attractive things going on.